[1]Sun,Haiying;Nikolovska-Coleska,Zaneta;Lu,Jianfeng;Meagher,JenniferL.;Yang,Chao-Yie;Qiu,Su;Tomita,York;Ueda,Yumi;Jiang,Sheng;Krajewski,Krzysztof;Roller,PeterP.;Stuckey,JeanneA.;Wang,Shaomeng[JournaloftheAmericanChemicalSociety,2007,vol.129,#49,p.15279-15294]
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization.
Journal: Bioorganic & medicinal chemistry 20121115
Title: Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis.
Journal: Breast cancer research and treatment 20120501
Title: LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.
Journal: Cancer research 20120301
Title: Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.
Journal: Molecular cancer therapeutics 20110401
Title: Sun H, et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc. 2007 Dec 12;129(49):15279-94.
Title: Lu J, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 2008 Nov 15;68(22):9384-93.
